Nasdaq · CIK 0001601485
ELTX Elicio Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 40 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Elicio Therapeutics, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 32 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Carol Gail Ashe director | AGrant or award Stock Option (Right to Buy)derivative | +21,750 | $0.00 | $0 | 21,750 | 40 d ago |
| Aug 31, 2026 | Julian Adams director | AGrant or award Stock Option (Right to Buy)derivative | +21,750 | $0.00 | $0 | 21,750 | 40 d ago |
| Aug 31, 2026 | Allen Nissenson director | AGrant or award Stock Option (Right to Buy)derivative | +21,750 | $0.00 | $0 | 21,750 | 40 d ago |
| Aug 31, 2026 | Jay Venkatesan director | AGrant or award Stock Option (Right to Buy)derivative | +21,750 | $0.00 | $0 | 21,750 | 40 d ago |
| Aug 31, 2026 | Karen J Wilson director | AGrant or award Stock Option (Right to Buy)derivative | +21,750 | $0.00 | $0 | 21,750 | 40 d ago |
| Aug 31, 2026 | Robert R Ruffolo director | AGrant or award Stock Option (Right to Buy)derivative | +21,750 | $0.00 | $0 | 21,750 | 40 d ago |
| Aug 31, 2026 | Yekaterina Chudnovsky director, owner | AGrant or award Stock Option (Right to Buy)derivative | +21,750 | $0.00 | $0 | 21,750 | 40 d ago |
| Jun 3, 2025 | Yekaterina Chudnovsky director, owner | AGrant or award Warrant (right to buy)derivativeindirect: Held by GKCC, LLC | +103,225 | $0.00 | $0 | 103,225 | Jun 4, 2025 |
| May 19, 2025 | Julian Adams director | AGrant or award Stock Option (Right to Buy)derivative | +7,900 | $0.00 | $0 | 7,900 | May 20, 2025 |
| May 19, 2025 | Carol Gail Ashe director | AGrant or award Stock Option (Right to Buy)derivative | +7,900 | $0.00 | $0 | 7,900 | May 20, 2025 |
| May 19, 2025 | Yekaterina Chudnovsky director, owner | AGrant or award Stock Option (Right to Buy)derivative | +7,900 | $0.00 | $0 | 7,900 | May 20, 2025 |
| May 19, 2025 | Robert R Ruffolo director | AGrant or award Stock Option (Right to Buy)derivative | +7,900 | $0.00 | $0 | 7,900 | May 20, 2025 |
| May 19, 2025 | Karen J Wilson director | AGrant or award Stock Option (Right to Buy)derivative | +7,900 | $0.00 | $0 | 7,900 | May 20, 2025 |
| May 19, 2025 | Jay Venkatesan director | AGrant or award Stock Option (Right to Buy)derivative | +7,900 | $0.00 | $0 | 7,900 | May 20, 2025 |
| May 19, 2025 | Allen Nissenson director | AGrant or award Stock Option (Right to Buy)derivative | +7,900 | $0.00 | $0 | 7,900 | May 20, 2025 |
| Apr 15, 2025 | Preetam Shah See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +191,624 | $0.00 | $0 | 191,624 | Apr 16, 2025 |
| Mar 5, 2025 | Yekaterina Chudnovsky director, owner | CConversion Common Stockindirect: Held by GKCC, LLC | +3,500,573 | $5.81 | $20M | 5,416,212 | Mar 7, 2025 |
| Mar 5, 2025 | Yekaterina Chudnovsky director, owner | CConversion Convertible Note (convertible into Common Stock)derivativeindirect: Held by GKCC, LLC | -3,442,341 | $5.81 | $20M | 0 | Mar 7, 2025 |
| Feb 3, 2025 | Robert Connelly CEO, President and Director | AGrant or award Stock Option (Right to Buy)derivative | +121,600 | $0.00 | $0 | 121,600 | Feb 4, 2025 |
| Feb 3, 2025 | Peter DeMuth Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +44,400 | $0.00 | $0 | 44,400 | Feb 4, 2025 |
| Feb 3, 2025 | Christopher Haqq See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Feb 4, 2025 |
| Dec 16, 2024 | Peter DeMuth Chief Scientific Officer | MOption exercise Common Stock | +381 | $4.41 | $1,680 | 381 | Dec 18, 2024 |
| Dec 16, 2024 | Peter DeMuth Chief Scientific Officer | MOption exercise Stock Option (Right to Buy)derivative | -381 | $0.00 | $0 | 0 | Dec 18, 2024 |
| Nov 26, 2024 | Jay Venkatesan director | XIn-the-money exercise Common Stock | +50,000 | $0.01 | $500 | 179,581 | Nov 29, 2024 |
| Nov 26, 2024 | Jay Venkatesan director | XIn-the-money exercise Warrant to Purchase Common Stockderivative | -50,000 | $0.00 | $0 | 0 | Nov 29, 2024 |
| Nov 21, 2024 | Julian Adams director | AGrant or award Stock Option (Right to Buy)derivative | +4,100 | $0.00 | $0 | 4,100 | Nov 25, 2024 |
| Nov 21, 2024 | Carol Gail Ashe director | AGrant or award Stock Option (Right to Buy)derivative | +4,100 | $0.00 | $0 | 4,100 | Nov 25, 2024 |
| Nov 21, 2024 | Yekaterina Chudnovsky director, owner | AGrant or award Stock Option (Right to Buy)derivative | +4,100 | $0.00 | $0 | 4,100 | Nov 25, 2024 |
| Nov 21, 2024 | Allen Nissenson director | AGrant or award Stock Option (Right to Buy)derivative | +4,100 | $0.00 | $0 | 4,100 | Nov 25, 2024 |
| Nov 21, 2024 | Robert R Ruffolo director | AGrant or award Stock Option (Right to Buy)derivative | +4,100 | $0.00 | $0 | 4,100 | Nov 25, 2024 |
| Nov 21, 2024 | Jay Venkatesan director | AGrant or award Stock Option (Right to Buy)derivative | +4,100 | $0.00 | $0 | 4,100 | Nov 25, 2024 |
| Nov 21, 2024 | Karen J Wilson director | AGrant or award Stock Option (Right to Buy)derivative | +4,100 | $0.00 | $0 | 4,100 | Nov 25, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Julian Adamsdirector
- Carol Gail Ashedirector
- Yekaterina Chudnovskydirector, owner
- Robert ConnellyCEO, President and Director
- Peter DeMuthChief Scientific Officer
- Christopher HaqqSee Remarks
- Allen Nissensondirector
- Robert R Ruffolodirector
- Preetam ShahSee Remarks
- Jay Venkatesandirector
- Karen J Wilsondirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.